NSABP B-57-I
NSABP B-57-I
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer (PALLAS) Global Accrual = 5793
Patient Population:
Patients with hormone receptor-positive, HER2-negative early-stage breast cancer
Target Accrual: 439 patients
Status: Not Recruiting
ClinicialTrials.gov Identifier: NCT02513394
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer (PALLAS) Global Accrual = 5793
Patient Population:
Patients with hormone receptor-positive, HER2-negative early-stage breast cancer
Target Accrual: 439 patients
Status: Not Recruiting
ClinicialTrials.gov Identifier: NCT02513394